Johnson & Johnson

7 tips for safer lens wear with cosmeticsA few tips regarding wearing cosmetics and contact lens wear can help our patients wear their lenses with more comfort.
Johnson & Johnson to acquire Abbott Medical Optics
Johnson & Johnson to acquire Abbott Medical OpticsReady for some big news? Johnson & Johnson announced they have entered into a definitive agreement to acquire Abbott Medical Optics (AMO) for $4.325 billion in cash. AMO’s business segments include cataract surgery, laser refractive surgery, and consumer eye health, and reported sales in 2015 were $1.1 billion.
Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.
Another win for biosimilar arthritis drugsIn another win for biosimilar drugs, FDA staff recently decided that Celltrion and Pfizer’s biosimilar (Remsima) to Johnson & Johnson’s Remicade for rheumatoid arthritis was “highly similar” to the branded drug.
J&J’s antibiotic faces $800M lawsuitJohnson & Johnson faces $800 million racketeering lawsuit over its antibiotic, Levaquin.
Anterior eye health recording: current methods and best practiceDr Wolffsohn presents the results of a survey completed by eye care practitioners worldwide regarding their current practices on anterior eye health recording. Recommendations on best practice are also presented, based on these study findings.
Adults surpass kids for ADHD scriptsMore adults than children in the United States now take medication for attention deficit hyperactivity disorder (ADHD), according to new data.
J&J-Achillion partner to develop hep C drugsJohnson & Johnson is expanding its reach in the lucrative hepatitis C drug market after announcing it will collaborate with Achillion Pharmaceuticals to develop its HCV drugs.
[BLOG] Pipeline advancement responsible for upturn in global pharma R&DThe world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013, an increase of $723 million over the previous year. According to our new Global Pharmaceutical Benchmark Report, Roche was the R&D spending leader, outlaying nearly $10 billion in 2013. Meanwhile, Novartis and Johnson & Johnson (J&J) increased their R&D spend the most between 2012 and 2013, with each adding around $500 million to their respective clinics. Novartis’ R&D spending grew by 5.6% to $9.8 billion, and J&J spent $8.2 billion, which was up by 6.8% from 2012.
What is new in the anticoagulant antidote market?The use of new oral anticoagulants (NOACs) continues to increase. Over the past 4 quarters, rivaroxaban (Xarelto, Bayer/Johnson & Johnson) and apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) were in the top 20 of fastest-growing drugs in the United States. They offer advantages compared to warfarin such as a rapid onset of action, no dietary modifications, fewer drug–drug interactions, and do not require routine coagulation monitoring.